## WEDNESDAY 20<sup>th</sup> JUNE 2012 COMMENCING 10.30 AM (UNTIL 4.00 PM APPROX)

## AT <u>CARDIFF METROPOLITAN UNIVERSITY</u>, LLANDAFF CAMPUS, WESTERN AVENUE, CARDIFF CF5 2YB

## **AGENDA**

**Enclosure** 1. Welcome and introduction 2. **Apologies** 3. **Declarations of interest** 4. Chairman's report (verbal update) 5. Minutes of previous meeting 1/AWMSG/0612 6. Appraisal 1 **2**/AWMSG/0612 Belatacept (Nulojix®) for prophylaxis of graft rejection in **Appendices** adults receiving a renal transplant, in combination with corticosteroids and a mycophenolic acid 7. 3/AWMSG/0612 **Appraisal 2** Nevirapine (Viramune®) 400 mg prolonged release tablets in **Appendices** combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults 4/AWMSG/0612 8. **Appraisal 3** Nevirapine (Viramune<sup>®</sup>) 50 mg, 100 mg, 400 mg prolonged **Appendices** release tablets in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adolescents and children three years and above and able to swallow tablets Appraisal 4 5/AWMSG/0612 Rilpivirine (Edurant®) in combination with other antiretroviral **Appendices** medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml 10. Appraisal 5 6/AWMSG/0612 **Rifaximin (Xifaxanta®▼)** for the treatment of travellers diarrhoea that **Appendices** is not associated with any of: fever, bloody diarrhoea, eight or more unformed stools in the previous 24 hours, occult blood or leucocytes

in the stool. Rifaximin (Xifaxanta®) may shorten the duration of diarrhoea when this is associated with non-invasive strains of E.coli

AWPAG Update (draft minutes - April 2012)
CEPP Repeat Prescribing Audit
Warfarin Monitoring
Monitored Dosage System Standards
7/AWMSG/0612
Monitored Dosage System Standards
10/AWMSG/0612

15. Date of next meeting - Wednesday, 18<sup>th</sup> July 2012 in Cardiff